Dr Reddy’s gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy’s Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy’s Holding Ltd (DRHL) with itself.

The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy’s Laboratories Ltd said in a regulatory filing.

It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy’s Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added.

“The notice quantifies the proposed demand of Rs 23,95,81,79,470,” the company said.

DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws.

“Further this was approved by the Honorable NCLT, Hyderabad on April 5, 2022 with effect from the appointed date April 1, 2019,” it added.

The company further said it strongly believes that there is no escaping of tax pursuant to the said merger scheme.

“Nonetheless the company is reviewing the information and clarifications required in the show cause notice and will respond, as required, appropriately,” it said.

DRL further said the scheme also provides that the promoters of the company will jointly and severally indemnify, defend and hold harmless the company, its directors, employees, officers, representatives, or any other person authorised by it (excluding the promoters) for any liability, claim, or demand, which may devolve upon the company on account of this amalgamation.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23